Pacira BioSciences, Inc.PCRX
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · pacira.com
Develops and commercializes non-opioid pain management products, including EXPAREL, ZILRETTA and iovera (being divested to Zimmer Biomet).
Key ratios
Operating cash flow growth
39.5%TTM
2025
-19.8%2024
22.5%2023
6.5%
EPS growth
160.7%2023
FCF / Sales
24.1%TTM
2025
18.8%2024
25.5%2023
20.7%
Net margin
2.0%TTM
2025
1.0%2024
-14.2%2023
6.2%
ROA
1.5%TTM
2025
1.5%2024
3.9%2023
3.4%
ROE
2.1%TTM
2025
1.0%2024
-12.1%2023
5.1%
Revenue growth
3.6%2025
2024
3.9%2023
1.2%
Track PCRX in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer